The Dominantly Inherited Alzheimer Network Trials Unit (DIAN‐TU) spearheads the TauNexGen trial, a Phase II/III initiative aimed at assessing the safety, tolerability, biomarkers, and cognitive effects of this anti‐tau investigational drug in symptomatic and asymptomatic individuals harboring AD‐causing genetic mutations.15 Here, MAPT is linked to Alzheimer disease.